Lorenzo Guglielmetti

Lorenzo Guglielmetti

Auto-generated profile, based on publicly available information

Lorenzo Guglielmetti

Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2020 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
CDCharles L. Daley
Charles L. Daley
JIJonathan M. Iaccarino
Jonathan M. Iaccarino
CLChristoph Lange
Christoph Lange
ECEmmanuelle Cambau
Emmanuelle Cambau
RWRichard J. Wallace
Richard J. Wallace
KWKevin L. Winthrop
Kevin L. Winthrop
Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii , and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.

14 August 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CDCharles L Daley
Charles L Daley
JIJonathan M Iaccarino
Jonathan M Iaccarino
CLChristoph Lange
Christoph Lange
ECEmmanuelle Cambau
Emmanuelle Cambau
RWRichard J Wallace
Richard J Wallace
KWKevin L Winthrop
Kevin L Winthrop
Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.

1 September 2018 in The Lancet
Verified
Journal Article
Closed access
NANafees Ahmad
Nafees Ahmad
SAShama D Ahuja
Shama D Ahuja
OAOnno W. Akkerman
Onno W. Akkerman
JAJan-Willem C Alffenaar
Jan-Willem C Alffenaar
LALaura F Anderson
Laura F Anderson
DMDick Menzies
Dick Menzies

14 August 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CDCharles L Daley
Charles L Daley
JIJonathan M Iaccarino
Jonathan M Iaccarino
CLChristoph Lange
Christoph Lange
ECEmmanuelle Cambau
Emmanuelle Cambau
RWRichard J Wallace
Richard J Wallace
KWKevin L Winthrop
Kevin L Winthrop
Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.

17 March 2020 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
ZLZhiyi Lan
Zhiyi Lan
NANafees Ahmad
Nafees Ahmad
PBParvaneh Baghaei
Parvaneh Baghaei
LBLinda Barkane
Linda Barkane
ABAndrea Benedetti
Andrea Benedetti
ZUZf Udwadia
Zf Udwadia

22 March 2018 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
JIJakko van Ingen
Jakko van Ingen
TATimothy Aksamit
Timothy Aksamit
CAClaire Andrejak
Claire Andrejak
EBErik C. Böttger
Erik C. Böttger
ECEmmanuelle Cambau
Emmanuelle Cambau
DWDirk Wagner
Dirk Wagner
Improving treatment outcome reporting in NTM disease: NTM-NET (@ntmnet) consensus statement on treatment outcome definitionshttp://ow.ly/c6IC30iwLM4